Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program

  • General Topics
  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

This study examined whether costs associated with tuberculosis (TB) screening and directly observed preventive therapy (DOPT) among drug injectors attending a syringe exchange are justified by cases and costs of active TB cases prevented and examined the impact of monetary incentives to promote adherence on cost-effectiveness. We examined program costs and projected savings using observed adherence and prevalence rates and literature estimates of isoniazid (INH) preventive therapy efficacy, expected INH hepatoxicity rates, and TB treatment costs; we conducted sensitivity analyses for a range of INH effectiveness, chest X-ray (CXR) referral adherence, and different strategies regarding anergy among persons affected with human immunodeficiency virus (HIV). For 1,000 patients offered screening, incorporating real observed program adherence rates, the program would avert $179,934 in TB treatment costs, for a net savings of $123,081. Assuming a modest risk of TB among HIV-infected anergic persons, all strategies with regard to anergy were cost saving, and the strategy of not screening for anergy and not providing DOPT to HIV-infected anergic persons resulted in the greatest cost savings. If an incentive of $25 per person increased CXR adherence from the observed 31% to 50% or 100%, over a 5-year follow-up the net cost savings would increase to $170,054 and $414,856, respectively. In this model, TB screening and DOPT at a syringe exchange is a cost-effective intervention and is cost-saving compared to costs of treating active TB cases that would have occurred in the absence of the intervention. This model is useful in evaluating the cost impact of planned program refinements, which can then be tested. Monetary incentives for those referred for screening CXRs would be justified on a cost basis if they had even a modest beneficial impact on adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Int Med. 1979;139:337–339.

    Article  CAS  Google Scholar 

  2. Perlman D, Salomon N, Perkins MP, Yancovitz S, Paone D, Des Jarlais DC. Tuberculosis in drug users. Clin Infec Dis. 1995;21:1253–1264.

    CAS  Google Scholar 

  3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–550.

    Article  CAS  PubMed  Google Scholar 

  4. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1969;17:28–106.

    Google Scholar 

  5. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO. 1982;60:555–564.

    Google Scholar 

  6. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935–943.

    CAS  PubMed  Google Scholar 

  7. Wadhawan D, Hira S, Mwanasa N, Tembo G, Perine PL. Preventive tuberculosis chemotherapy with isoniazid among persons infected with HIV-1. In: Ninth International Conference on AIDS; June 6–11, 1993; Berlin, Germany. Abstract PO-BO7-1114.

  8. Pape JJW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342: 268–272.

    Article  CAS  PubMed  Google Scholar 

  9. Whalen C, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801–808.

    Article  CAS  PubMed  Google Scholar 

  10. Halsey N, Coberly J, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998; 351:786–792.

    Article  CAS  PubMed  Google Scholar 

  11. Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis. 1997;1:101–109.

    CAS  PubMed  Google Scholar 

  12. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the US. Arch Intern Med. 1995;155:1595–1600.

    Article  CAS  PubMed  Google Scholar 

  13. Sawert H, Girardi E, Antonucci G, et al. Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. Arch Int Med. 1998;158:2112–2121.

    Article  CAS  Google Scholar 

  14. Aisu T, Raviglione MC, van Pragg E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing centre. AIDS. 1995;9:267–272.

    CAS  PubMed  Google Scholar 

  15. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive program on return rates for PPD test reading in patients with HIV infection. J AIDS. 1996;11:455–459.

    CAS  Google Scholar 

  16. Malotte CK, Rhodes F, Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796.

    Article  CAS  PubMed  Google Scholar 

  17. Geiter L. Preventive therapy for tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: a Comprehensive International Approach. New York: Marcel Decker; 1993: 241–248.

    Google Scholar 

  18. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247.

    Google Scholar 

  19. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis. 1996;15:93–104.

    Article  CAS  PubMed  Google Scholar 

  20. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345:1545–1548.

    Article  CAS  PubMed  Google Scholar 

  21. Nolan CM. Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection. Clin Infect Dis. 1999;29:880–887.

    Article  CAS  PubMed  Google Scholar 

  22. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1993;32:135.

    Google Scholar 

  23. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus infection (HIV) in a methadone maintenance program. Ann Int Med. 1989;111:761–763.

    CAS  PubMed  Google Scholar 

  24. Centers for Disease Control and Prevention. Tuberculosis prevention in drug treatment centers and correctional facilities—selected US sites, 1990–1991. MMWR Morb Mortal Wkly Rep. 1993;42:210–213.

    Google Scholar 

  25. Gourevitch M, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis. 1998;2:531–540.

    CAS  PubMed  Google Scholar 

  26. US Congress, Office of Technology Assessment. The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection. Washington, DC: US Congress, Office of Technology Assessment; September 1990.

    Google Scholar 

  27. Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange. Am J Public Health. 1997;87:862–863.

    CAS  PubMed  Google Scholar 

  28. Paone D, Perlman DC, Perkins MP, Kochems LM, Salomon N, Des Jarlais DC. Organizational issues in conducting tuberculosis screening at a syringe exchange. J Subst Abuse Treat. 1998;15:229–234.

    Article  CAS  PubMed  Google Scholar 

  29. Perlman DC, Salomon N, Ziluck V, Freidmann P. Tuberculosis directly observed preventive therapy for active drug users. Paper presented at: 126th Annual Meeting of the American Public Health Association. November 15–18, 1998; Washington, DC. Session 2315, p. 286.

  30. American Thoracic Society/Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–1395.

    Google Scholar 

  31. Snider DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA. 1986;225:1579–1583.

    Article  Google Scholar 

  32. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258.

    Article  CAS  PubMed  Google Scholar 

  33. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172–1177.

    Article  CAS  PubMed  Google Scholar 

  34. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339–1341.

    Article  CAS  PubMed  Google Scholar 

  35. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med. 1988;4:102–109.

    CAS  PubMed  Google Scholar 

  36. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the US among HIV-infected persons. Ann Intern Med. 1997;126:123–132.

    CAS  PubMed  Google Scholar 

  37. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;321:874–879.

    Google Scholar 

  38. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321:874–879.

    Article  CAS  PubMed  Google Scholar 

  39. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992; 268:504–509.

    Article  CAS  PubMed  Google Scholar 

  40. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med. 1993;119:194–198.

    CAS  PubMed  Google Scholar 

  41. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med. 1997;337:315–320.

    Article  CAS  PubMed  Google Scholar 

  42. Arno PS, Murray CJL, Bonuck KA, Alcabes P. The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis. J Law Med Ethics. 1993;21: 317–323.

    Article  CAS  PubMed  Google Scholar 

  43. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in person with HIV infection. Am J Respir Crit Care Med. 1996;153:1982–1984.

    CAS  PubMed  Google Scholar 

  44. Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med. 1995;155:2111–2117.

    Article  CAS  PubMed  Google Scholar 

  45. Klein RS, Flanigan T, Schuman P, Smith D, Vlahov D. Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. J Allergy Clin Immunol. 1999;103: 93–98.

    Article  CAS  PubMed  Google Scholar 

  46. Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep. 1997;46(RR-15):1–10.

    Google Scholar 

  47. Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS. 1999;13:2069–2074.

    Article  CAS  PubMed  Google Scholar 

  48. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis. 1991;144:745–749.

    CAS  PubMed  Google Scholar 

  49. Goldstein S, Perlman DC, Salomon N. Two stage tuberculin skin testing in an HIV-infected population: a preliminary report. Mt Sinai J Med. 1994;61:337–340.

    CAS  PubMed  Google Scholar 

  50. Perlman DC, Hanvanich M. Prophylaxis and treatment of HIV-related tuberculosis. AIDS. 1997;11(suppl):S173-S179.

    Article  PubMed  Google Scholar 

  51. Raviglione MC, Sudre P, Reider HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull WHO. 1993;71:297–306.

    CAS  PubMed  Google Scholar 

  52. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on site primary care services in a methadone maintenance program. Public Health Rep. 1993;108:492–500.

    CAS  PubMed  Google Scholar 

  53. Paone D, Clark J, Shi Q, Purchase D, Des Jarlais DC. Syringe exchange in the US, 1996: a national profile. Am J Public Health. 1999;89:43–46.

    CAS  PubMed  Google Scholar 

  54. Carvell AM, Hart GJ. Help-seeking and referrals in a needle exchange: a comprehensive service to injecting drug users. Br J Addict. 1990;1990:85:235–240.

    Article  Google Scholar 

  55. Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice F. Three years of needle exchange in New Haven: What have we learned? AIDS Public Policy J. 1994;9:59–62.

    Google Scholar 

  56. Stancliff S, Salomon N, Perlman DC, Russell PC. Provision of influenza and pneumococcal vaccine to injection drug users at a syringe exchange. J Subst Abuse Treat. 2000;18: 263–265.

    Article  CAS  PubMed  Google Scholar 

  57. Nagamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chaing Rai, Thailand. AIDS. 1997;11:107–112.

    Article  Google Scholar 

  58. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV infected persons: a prospective cohort study. JAMA. 1995;274:143–148.

    Article  CAS  PubMed  Google Scholar 

  59. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345–1349.

    Article  CAS  PubMed  Google Scholar 

  60. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adult. Int J Tuberc Lung Dis. 1999;3:847–850.

    CAS  PubMed  Google Scholar 

  61. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985–1991.

    Article  CAS  PubMed  Google Scholar 

  62. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone with-drawal. N Engl J Med. 1976;294:1104–1106.

    Article  CAS  PubMed  Google Scholar 

  63. Curtis R, Friedman SR, Neaigus A, et al. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 1994;109:319–327.

    CAS  PubMed  Google Scholar 

  64. Marks SM, Taylor Z, Burrows NR, Qayad MG, Miller B. Hospitalization of homeless persons with tuberculosis in the US. Am J Public Health. 2000;90:435–438.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montefiore Medical Center, Bronx, New York

    Marc N. Gourevitch

  2. Beth Israel Medical Center, First Avenue at 16th Street, 10003, New York, NY

    David C. Perlman MD,  Chau Trinh,  Nadim Salomon,  Leslie Horn &  Don C. Des Jarlais

Authors
  1. David C. Perlman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc N. Gourevitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chau Trinh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadim Salomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leslie Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Don C. Des Jarlais
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Perlman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perlman, D.C., Gourevitch, M.N., Trinh, C. et al. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health 78, 550–567 (2001). https://doi.org/10.1093/jurban/78.3.550

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/78.3.550

Keywords

Search

Navigation